ResMed (NYSE: RMD), a technology-focused medical device company, has agreed to purchase Brightree, a business management and clinical software applications company for the post-acute care industry. ResMed will finance the $800 million all-cash purchase with debt.

Brightree reported net sales of $113 million and EBITDA of about $43 million for 2015.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.